Author

J. L. Wolf

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1 Approach:statistical model· 1

Frequent Co-Authors

A. P. Wiita· 3 shared N. Shah· 3 shared P. Choudhry· 3 shared S. W. Wong· 3 shared T. G. Martin· 3 shared I. D. Ferguson· 2 shared Y.-H. T. Lin· 2 shared A. B. Abarientos· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. P. Wiita

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

I. D. Ferguson, B. P. Escobar, S. T. Tuomivaara, Y.-H. T. Lin, M. A. Nix, K. K. Leung, M. Hale, P. Choudhry, A. Lopez-Girona, E. Ramos, S. W. Wong, J. L. Wolf, T. G. Martin, N. Shah, S. Vandenberg, , A. P. Wiita

This study defines the myeloma cell surface proteome, identifies therapeutic targets and resistance biomarkers, and presents a miniaturized surface proteomics protocol.

bioRxiv · Jan 17, 2021Cancer Biology

CRISPR-based screens uncover determinants of immunotherapy response in Multiple Myeloma

P. Ramkumar, A. B. Abarientos, R. Tian, M. Seyler, J. T. Leong, M. Chen, P. Choudhry, T. Hechler, N. Shah, S. W. Wong, T. G. Martin, J. L. Wolf, K. T. Roybal, A. Pahl, J. Taunton, , M. Kampmann

This study uses CRISPR screens to identify mechanisms increasing BCMA expression and enhancing anti-myeloma efficacy of BCMA-targeted therapies in multiple myeloma.

bioRxiv · Apr 14, 2020Cancer Biology

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

H. H.-L. Huang, I. D. Ferguson, A. M. Thornton, C. Y. T. Lam, Y.-H. T. Lin, P. Bastola, P. Choudhry, M. C. Mariano, M. D. Marcoulis, J. Malato, P. Phojanakong, T. G. Martin, J. L. Wolf, S. W. Wong, N. Shah, , A. P. Wiita

The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.

bioRxiv · Feb 3, 2019Cancer Biology